Data from a Phase 1/2 clinical inq...
Data from a Phase 1/2 clinical inquiry of MVA-BN nef vaccine demonstrates that Bavarian Nordic's (Copenhagen, Denmark) result induces an HIV-specific immune answer and exhibits a strong safety profile in HIV-infected individuals. Fourteen HIV-infected enslaves with CD4 > 400 copies/[micro]L were vaccinated with 5 X 108 TCID50 of the returns in a prime-boost setting (week 0 4 16) A preliminary report upon safety and immunogenicity after completion of the therapy phase of the investigation revealed a strong ...
|